| Name: |
HALOPERIDOL (HaldolR) |
| Classification: |
antipsychotic, anxiolytic |
| Dose: |
- Intermittent Bolus Dose:
- 2.5-5 mg as IV infusion q 30 min - q6h
- Continuous Infusion:
- 1-10 mg/hr, with additional 1-10 mg bolus prn up to every 30-60 minutes
|
| Administration: |
IV Infusion:
100 mg in 100 ml of dextrose 5% (maximum concentration of 3 mg/ml) |
| Adverse Effects: |
- tachycardia
- hypotension or hypertension
- CNS: ataxia, fixed stare, tardive dyskinesia, tardive dystonia, insomnia, restlessness, agitation, seizures
- exacerbation of psychotic symptoms
- dry mouth or hypersalivation
- constipation
- anemia, leukopenia
- QT interval prolongation; Torsades de Pointes
- elevated liver enzymes
|
| Drug Interactions: |
- haloperidol + CNS depressants = increased sedation
- haloperidol + anticholinergic agents = increased anticholinergic effects
|
| Monitoring Therapy: |
- blood pressure
- heart rate
- QT interval
- mental status
- delirum screen
- liver enzymes
- muscular tone and signs of extrapyramidal symptoms
- skin
|
| Adult Critical Care Protocol: |
- May be administed IV direct or by IV infusion by a nurse in Adult Critical Care
- Continuous infusions must be administered by infusion device with pump library enabled.
|
